The University of Colorado Cancer Center (UCCC) is the only NCI-designated comprehensive Cancer Center in the Rocky Mountain region - an area with a population of approximately eight million people. The goals are to reduce the cancer burden by: 1) conducting coordinated and interdisciplinary basic, clinical, translation, prevention and control, population, and educational research, 2) providing citizens of Colorado and the Rocky Mountain region with state-of-the art programs in cancer research, therapy, early detection, prevention and control, and 3) providing cancer education at all levels from students to the public sector. There are 271 full and 110 associate members who participate in one or more of the UCCC's eight programs including Cancer Cell Biology, Molecular and Structural Biology, Immunology and Immunotherapy, Hormone Related Malignancies, Tobacco Related Malignancies, Developmental Therapeutics, Carcinogenesis and Chemoprevention, and Clinical and Community Cancer Prevention and Control. Over the past five years, the NCI sponsored research portfolio has nearly doubled from $21 million to $39.7 million, excluding the CCSG. This was accomplished largely through the successful funding of major new collaborative NCI grants and contracts totaling more than $7 million annually and through the recruitment of 100 new members who hold more than $14 million in NCI grant support. Over the past five years, the number of subjects accrued to clinical trials and the number of outpatient visits have also doubled. The Cancer Center is a """"""""matrix"""""""" Cancer Center within the University of Colorado Denver and Health Sciences Center and we are applying as a consortium with members from the University of Colorado at Boulder campus, the AMC Cancer Research Center, the National Jewish Medical and Research Center, and the Colorado State University campuses. These consortium members strengthen and broaden cancer research activities. Member research is supported by 15 shared core resources, of which the Informatics shared resource and the Structural Biology shared resource are new. Major new services and equipment were added to most of the shared resources. Center members also benefit from the Development activities of the Cancer Center that bring new recruitments, pilot projects and shared facilities. Planning and evaluation efforts have allowed our on-going move to the new Fitzsimons campus to provide state-of-the art facilities and increased collaborations. The completion of the new campus will allow continued growth over the next five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-23
Application #
7763867
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-04-04
Project End
2012-01-31
Budget Start
2010-02-01
Budget End
2012-01-31
Support Year
23
Fiscal Year
2010
Total Cost
$4,205,819
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Cao, Shengya; Zhou, Keda; Zhang, Zhening et al. (2018) Constitutive centromere-associated network contacts confer differential stability on CENP-A nucleosomes in vitro and in the cell. Mol Biol Cell 29:751-762
Petersen, Dennis R; Saba, Laura M; Sayin, Volkan I et al. (2018) Elevated Nrf-2 responses are insufficient to mitigate protein carbonylation in hepatospecific PTEN deletion mice. PLoS One 13:e0198139
Merrick, Daniel T; Edwards, Michael G; Franklin, Wilbur A et al. (2018) Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res 78:4971-4983
Hintzsche, Jennifer D; Yoo, Minjae; Kim, Jihye et al. (2018) IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics. BMC Med Genomics 11:26
Korch, Christopher; Hall, Erin M; Dirks, Wilhelm G et al. (2018) Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. Int J Cancer 142:561-572
Marwan, Ahmed I; Shabeka, Uladzimir; Reisz, Julie A et al. (2018) Unique Heterogeneous Topological Pattern of the Metabolic Landscape in Rabbit Fetal Lungs following Tracheal Occlusion. Fetal Diagn Ther :
Li, Howard Y; McSharry, Maria; Walker, Deandra et al. (2018) Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II. Oncoimmunology 7:e1423182
Goldstein, Nathaniel B; Koster, Maranke I; Jones, Kenneth L et al. (2018) Repigmentation of Human Vitiligo Skin by NBUVB Is Controlled by Transcription of GLI1 and Activation of the ?-Catenin Pathway in the Hair Follicle Bulge Stem Cells. J Invest Dermatol 138:657-668
Kumar, Rahul; Deep, Gagan; Wempe, Michael F et al. (2018) Procyanidin B2 3,3?-di-O-gallate induces oxidative stress-mediated cell death in prostate cancer cells via inhibiting MAP kinase phosphatase activity and activating ERK1/2 and AMPK. Mol Carcinog 57:57-69
Richmond, Craig S; Oldenburg, Darby; Dancik, Garrett et al. (2018) Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth. Oncotarget 9:16718-16730

Showing the most recent 10 out of 1634 publications